Collectively, these results demonstrate that X15695 inhibits proliferation of breast cancer cells and prostate cancer cells but its strong effect on the degradation of ERα combined with the reactivation of p53 makes it a superior inhibitor of ER+ breast cancer cells than AR+ prostate cancer cells. This evidence concerns the gene ESR1 and prostate carcinoma.